Tag Archive for: the psychedelic investor
Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin
Business, Research
Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it.
The Phase-2…
Why Psychedelic Stocks Have Crashed in the Last 3 Months
BusinessOur resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.